▲ 4.45%
prev close
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Congressional Trades
2
All tracked trades
Members Trading
2
Unique members
Net Activity
+0
1 buys · 1 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2022-03-30 | NEONeogenomics, Inc. | Sell | $1,001 - $15,000 | 1438d ago | — | |
| 2021-12-30 | NEONeogenomics, Inc. | Buy | $15,001 - $50,000 | 1545d ago | — |
2022-03-30
Dwight Evans
NEO
Amount
$1,001 - $15,000
Filed
1438d ago
2021-12-30
Deborah K. Ross
NEO
Amount
$15,001 - $50,000
Filed
1545d ago
Recent News
Powered by Polygon.io
3 Hot Trades for Insiders, But Are They Good Buys for Investors?
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
Not Just a DEX: How Pineapple’s Mystery Marketing is Changing the Game
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
Trade Timeline
Congressional activity, newest first
Dwight Evans
2022-03-30 · Sale
$1,001 - $15,000
Deborah K. Ross
2021-12-30 · Purchase
$15,001 - $50,000